Skip to Main Content

Advertisement

Skip Nav Destination

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma

Blood Adv (2017) 1 (24): 2247–2256.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement